skip to Main Content

August 9, 2013

Codexis Reports Second Quarter 2013 Results

— Conference call on August 15th at 4:30 pm
ET

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Aug. 9, 2013–
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced
financial results for the second quarter ended June 30, 2013.

“We continued to make significant progress with all of our value-driving
business platforms in recent months,” said John Nicols, President and
CEO of Codexis. “We continued to build on our core pharmaceutical
business, expanding our pipeline opportunities through a collaboration
with Purolite around immobilized enzymes and with the addition of a new
head of sales and marketing. We also delivered on our commitment to
expand into other complex chemistry markets beyond pharmaceuticals by
signing a joint development agreement with a market-leading food
ingredients company and delivering the first commercial shipment to a
separate company of an enzyme used for producing a food additive.”

Nicols continued, “Additionally, we recently achieved scale-up in the
production of CodeXol® detergent alcohols with our partner
Chemtex, which we believe is the first successful effort to produce
large-scale commercially-relevant detergent alcohols from cellulosic
biomass feedstock. Regarding our CodeXyme® program, we
recently received a letter from Dyadic alleging that we breached our
obligations under the license agreement that we entered into with Dyadic
in 2008. We strongly believe that we are not in breach of the Dyadic
license agreement and that Dyadic’s allegation is unjustified and
without legal or factual basis, and we are considering all available
remedies to protect our interests under the Dyadic license agreement.”

Recent Business Highlights:

  • Entered into a joint development agreement with a large, global
    manufacturer of food and beverage ingredients;
  • Delivered our first commercial enzyme shipment for production of a
    food additive;
  • Established a joint collaboration with Purolite Corporation to develop
    and market immobilized enzymes and immobilized enzyme kits for the
    pharmaceutical industry;
  • Achieved successful scale-up with Chemtex in the production of CodeXol®
    detergent alcohols using cellulosic sugars from non-food biomass; and
  • Appointed industry veteran Scott Watson as Vice President of Sales and
    Marketing.

Second Quarter Financial Highlights:

Revenues for the second quarter of 2013 were $7.0 million, a 39%
decrease from $11.5 million in the first quarter of 2013. Revenues for
the six months ended June 30, 2013 were $18.5 million. Product revenue
in the second quarter of 2013 was $5.0 million, a 45% decrease from $9.1
million
in the first quarter of 2013. The decrease in product revenue
was primarily due to weakness in our atorvastatin business. Product
revenue for the six months ended June 30, 2013 was $14.1 million.
Product gross margin in the second quarter was 27%, compared to 38% in
the first quarter of 2013. Product gross margin for the six months ended
June 30, 2013 was 34%. Collaborative research and development revenue
for the second quarter of 2013 was $2.0 million, a decrease of 13% from
$2.3 million in the first quarter of 2013.

Research and development expenses in the second quarter of 2013 were
$8.6 million, an increase of 18% from $7.3 million for the first quarter
of 2013. Selling, general and administrative expenses in the second
quarter of 2013 were $7.2 million, a decrease of 11% compared to $8.1
million
in the first quarter of 2013.

Changes in both research and development and selling, general and
administrative expenses compared to the prior quarter were related to
further re-alignment among departments following the significant
organizational changes begun late last year. When combined, operating
expenses (research and development plus selling, general and
administrative) increased slightly to $15.8 million in the second
quarter, up 2% from $15.5 million in the first quarter of 2013. The
increase was primarily due to a charge of $0.4 million to write-down
supplier advances for which recovery was determined to be uncertain.

Net loss was $12.6 million, or a loss of $0.33 per share, based on 38.1
million weighted average common shares outstanding in the second quarter
of 2013. This compares to a net loss of $9.6 million, or a loss of $0.25
per share, during the first quarter of 2013. Net loss for the six months
ended June 30, 2013 was $22.2 million, or a loss of $0.59 per share,
based on 38.0 million weighted average common shares outstanding during
the period.

Cash, cash equivalents, and marketable securities at June 30, 2013 were
$38.9 million compared to $46.1 million at March 31, 2013.

As we have previously disclosed for our first quarter of 2013 results,
we will not be presenting year-over-year comparisons for the first three
quarters of 2013. Codexis does not believe that these comparisons are an
appropriate measure of the company’s financial performance due to the
termination of the Collaborative Research Agreement with Shell,
effective August 31, 2012, and the resulting loss of associated
collaborative research & development revenue.

Financial Outlook

Codexis’ statements with regard to its outlook are based on current
expectations. The following statements are forward looking, and actual
results could differ materially depending on market conditions and the
factors set forth under “Forward-Looking Statements” below.

Codexis is adjusting its prior outlook for the full year 2013. Codexis
continues to expect total pharmaceutical revenues in the range of $35
million to $40 million
. However, the company now expects product revenue
to be approximately $25 million of that total. Codexis continues to
expect product gross margin in the range of 30% to 35% and total gross
margin for pharmaceutical revenue of approximately 50%. Codexis is
adjusting its prior guidance for cash burn to now be in the range of $16
million to $19 million
for the year. Codexis had previously disclosed
its plan to secure a funding partner for its CodeXyme®
cellulase enzyme program by mid-2013. This process is ongoing, but has
taken longer than expected and now has been complicated by the recent
letter received from Dyadic. The actual cash burn for 2013 will be
dependent on if and when Codexis secures a funding partner for this
program.

Conference Call and Webcast

Codexis will hold a live conference call and audio webcast on Thursday,
August 15, 2013
, at 4:30 p.m. Eastern Time. The conference call dial-in
numbers are 877-415-3177 for domestic and 857-244-7320 for
international. Please use the pass code 60099547 and call approximately
10 minutes prior to start time. A live webcast of the call will also be
available from the Investors section of www.codexis.com.
A recording of the call will be available by calling 888-286-8010 for
domestic or 617-801-6888 for international, beginning approximately two
hours after the call, and will be available for up to seven days. Please
use the pass code 45333989 to access the replay. A webcast replay will
also be available from the Investors section of www.codexis.com
approximately two hours after the call, and will be available for up to
30 days.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to
Codexis’ forecast for 2013 total pharmaceutical revenue, total product
revenue, product gross margin, total gross margin for pharmaceutical
revenue and total cash burn; Codexis’ ability to expand its
pharmaceutical development pipeline, our consideration of possible
actions in response to allegations made by Dyadic International, Inc.
(“Dyadic”) that we breached our 2008 license agreement with Dyadic and
our need to secure third-party funding for our CodeXyme® cellulase
enzyme program. You should not place undue reliance on these
forward-looking statements because they involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond Codexis’
control and that could materially affect actual results. Factors that
could materially affect actual results include Codexis’ dependence on
obtaining third-party funding, or identifying and effecting some other
strategic option for, its CodeXyme® cellulase enzymes and CodeXol®
detergent alcohols programs; Codexis’ need for substantial additional
capital in the future in order to expand its business; Codexis’ ability
to maintain license rights granted from Dyadic to the commercial
expressions system for enzymes that Codexis uses in its CodeXyme®
cellulase enzyme program; uncertainty around Codexis’ ability to resolve
the dispute with Dyadic on commercially reasonable terms; uncertainty
around Codexis’ ability to dispute with success, through legal action or
otherwise, Dyadic’s allegation that Codexis has materially breached the
Dyadic license agreement; uncertainty around Codexis’ ability to buy or
license an expression system from another party or develop the
expression system itself; uncertainty about whether Codexis would be
able to secure third-party collaboration funding, or effect other
strategic options, for its CodeXyme® cellulase enzyme program in the
context of a dispute with Dyadic or in the absence of a license from
Dyadic; Codexis’ ability to maintain internal control over financial
reporting; any impairments Codexis may be required to record in the
future with respect to its goodwill, intangible assets or other
long-lived assets; the success of cost saving measures Codexis undertook
following the termination of the Shell collaboration, including Codexis’
2012 reduction in force, Codexis’ dependence on a limited number of
products and customers in its pharmaceutical business; Codexis’ primary
reliance on one contract manufacturer for commercial scale production of
substantially all of its enzymes; Codexis’ ability to develop and
commercialize new products for the pharmaceutical markets; Codexis’
relationships with, and dependence on, its collaborators in its
principal markets; Codexis’ ability to deploy its technology platform in
new adjacent market spaces; the success of customers’ pharmaceutical
products in the market and the ability of such customers to obtain
regulatory approvals for products and processes; Codexis’ pharmaceutical
product gross margins are variable and may decline from quarter to
quarter; Arch Pharmalabs Ltd’s ability to effectively market and sell
certain pharmaceuticals products containing Codexis’ technology; various
challenges to the feasibility of the production and commercialization of
biofuels and bio-based chemicals derived from cellulosic biomass;
potential reduction in demand for commercial products using Codexis’
technology as a result of fluctuations in the price of and demand for
certain commodities; and Codexis’ biofuel and bio-based chemicals
business opportunities may be limited by the availability, cost or
location of feedstocks. Additional factors that could materially affect
actual results can be found in Codexis’ Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 9, 2013,
including under the caption “Risk Factors.” Codexis expressly disclaims
any intent or obligation to update these forward-looking statements,
except as required by law.

 
Codexis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In
Thousands, Except Per Share Amounts)
         
Three Months Ended Six Months Ended
June 30,
2013
March 31,
2013
June 30,
2012
June 30,
2013
June 30,
2012
Revenues:
Product $ 4,948 $ 9,137 $ 6,782 $ 14,085 $ 21,949
Collaborative research and development 2,026 2,344 15,868 4,370 30,480
Government awards           259         1,616  
 
Total revenues   6,974     11,481     22,909     18,455     54,045  
 
Costs and operating expenses:
Cost of product revenues 3,631 5,665 5,829 9,296 18,471
Research and development 8,624 7,322 15,650 15,946 31,999
Selling, general and administrative   7,169     8,124     6,789     15,293     16,184  
 
Total costs and operating expenses   19,424     21,111     28,268     40,535     66,654  
 
Loss from operations (12,450 ) (9,630 ) (5,359 ) (22,080 ) (12,609 )
 
Interest income 16 27 74 43 149
Other expenses   (183 )   (85 )   (157 )   (268 )   (275 )
 

Loss before provision (benefit) for income taxes

(12,617 ) (9,688 ) (5,442 ) (22,305 ) (12,735 )
 

Provision (benefit) for income taxes

  (12 )   (65 )   77     (77 )   274  
 
Net loss $ (12,605 ) $ (9,623 ) $ (5,519 ) $ (22,228 ) $ (13,009 )
 
Net loss per share, basic and diluted $ (0.33 ) $ (0.25 ) $ (0.15 ) $ (0.59 ) $ (0.36 )
 
Weighted average common shares used in computing net loss per share,
basic and diluted
38,060 37,842 36,296 37,951 36,177
 
Codexis, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In
Thousands)
   
June 30,
2013
December 31,
2012
Assets
Current assets:
Cash and cash equivalents $ 32,392 $ 32,003
Marketable securities 5,512 13,524
Accounts receivable, net 1,591 7,545
Inventories 1,332 1,302
Prepaid expenses and other current assets   2,280     5,395  
Total current assets 43,107 59,769
 
Restricted cash 1,111 1,511
Non-current marketable securities 1,017 3,623
Property and equipment, net 15,520 16,650
Intangible assets, net 11,247 12,934
Goodwill 3,241 3,241
Other non-current assets   363     2,237  
Total assets $ 75,606   $ 99,965  
 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 1,545 $ 3,654
Accrued compensation 3,335 3,495
Other accrued liabilities 3,900 6,948
Deferred revenues   2,365     2,186  
Total current liabilities 11,145 16,283
 
Deferred revenues, net of current portion 1,207 1,299
Other long-term liabilities   3,783     3,943  
Total liabilities 16,135 21,525
 
Stockholders’ equity:
Common stock 4 4
Additional paid-in capital 297,144 294,128
Accumulated other comprehensive loss 106 (136 )
Accumulated deficit   (237,783 )   (215,556 )
Total stockholders’ equity   59,471     78,440  
Total liabilities and stockholders’ equity $ 75,606   $ 99,965  

Source: Codexis, Inc.

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma
Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk

Back To Top
Close search
Search